Advanced Search

Submit Manuscript

Volume 33, No 5, May 2023

ISSN: 1001-0602 
EISSN: 1748-7838 2018 
impact factor 17.848* 
(Clarivate Analytics, 2019)

Volume 33 Issue 5, May 2023: 337-338


EMP1+ tumor cells drive metastatic relapse

Oscar E. Villarreal , Scott Kopetz*

Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Correspondence: Scott Kopetz(

Disease relapse after surgical management in patients with early-stage colorectal cancer remains a significant clinical challenge due to its high incidence and lack of efficacious therapeutic interventions. In a recent study, Canellas-Socias et al. demonstrate that EMP1+ tumor cells are responsible for metastatic relapse and can be targeted by neoadjuvant immunotherapy to improve outcomes.


Browse 78